Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Detalles Bibliográficos
Autores principales: Russo, Alessandro, Scilla, Katherine A., Rolfo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797642/
https://www.ncbi.nlm.nih.gov/pubmed/35117140
http://dx.doi.org/10.21037/tcr.2019.06.24
_version_ 1784641600855474176
author Russo, Alessandro
Scilla, Katherine A.
Rolfo, Christian
author_facet Russo, Alessandro
Scilla, Katherine A.
Rolfo, Christian
author_sort Russo, Alessandro
collection PubMed
description
format Online
Article
Text
id pubmed-8797642
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87976422022-02-02 Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial Russo, Alessandro Scilla, Katherine A. Rolfo, Christian Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8797642/ /pubmed/35117140 http://dx.doi.org/10.21037/tcr.2019.06.24 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Russo, Alessandro
Scilla, Katherine A.
Rolfo, Christian
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title_full Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title_fullStr Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title_full_unstemmed Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title_short Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
title_sort long-term efficacy of immune checkpoint inhibitors in advanced nsclc: challenges and opportunities—a commentary of the 3-year follow-up of the keynote-001 trial
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797642/
https://www.ncbi.nlm.nih.gov/pubmed/35117140
http://dx.doi.org/10.21037/tcr.2019.06.24
work_keys_str_mv AT russoalessandro longtermefficacyofimmunecheckpointinhibitorsinadvancednsclcchallengesandopportunitiesacommentaryofthe3yearfollowupofthekeynote001trial
AT scillakatherinea longtermefficacyofimmunecheckpointinhibitorsinadvancednsclcchallengesandopportunitiesacommentaryofthe3yearfollowupofthekeynote001trial
AT rolfochristian longtermefficacyofimmunecheckpointinhibitorsinadvancednsclcchallengesandopportunitiesacommentaryofthe3yearfollowupofthekeynote001trial

Ejemplares similares